ALTERITY THERAPEUTICS LIMITED — Director's Dealing 2012

Dec 11, 2012

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: Prana Biotechnology Limited (ASX:PBT) ACN: 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Mr. Geoffrey Kempler Date of Last Notice: 4[th] January 2012

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		12thDecember 2012
No. of securities held prior to change				Options - - -
			Shares	Options
		Direct	30,000	-
		Indirect	17,625,000	-
		**Total **	17,655,000	-
Class		Unlisted Options
Number acquired				Options 4,000,000 - 4,000,000
			Shares	Options
		Direct	-	4,000,000
		Indirect	-	-
		Total	-	4,000,000

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		**Total **	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		As detailed in the Explanatory Memorandum which accompanied and formed part of the 2012 Notice of Annual General Meeting of the Company.
No. of securities held after change				Options 4,000,000 - 4,000,000
			Shares	Options
		Direct	30,000	4,000,000
		Indirect	17,625,000	-
		Total	17,655,000	4,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Issued in accordance with Resolution 5 as approved by shareholders at the Company’s Annual General Meeting held on 12thDecember 2012.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded No during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to N/A proceed during this period? If prior written clearance was provided on what date was this N/A provided?

The CFO Solution

12 Dec 2012

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: Prana Biotechnology Limited (ASX:PBT) ACN: 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Dr. George Mihaly Date of Last Notice: 3[rd] November 2010

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		12thDecember 2012
No. of securities held prior to change				Options - - -
			Shares	Options
		Direct	166,666	-
		Indirect	60,000	-
		**Total **	226,666	-
Class		Unlisted Options
Number acquired				Options 1,000,000 - 1,000,000
			Shares	Options
		Direct	-	1,000,000
		Indirect	-	-
		Total	-	1,000,000

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		**Total **	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		As detailed in the Explanatory Memorandum which accompanied and formed part of the 2012 Notice of Annual General Meeting of the Company.
No. of securities held after change				Options 1,000,000 - 1,000,000
			Shares	Options
		Direct	166,666	1,000,000
		Indirect	60,000	-
		Total	226,666	1,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Issued in accordance with Resolution 5 as approved by shareholders at the Company’s Annual General Meeting held on 12thDecember 2012.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded No during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to N/A proceed during this period? If prior written clearance was provided on what date was this N/A provided?

The CFO Solution

12 Dec 2012

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: Prana Biotechnology Limited (ASX:PBT) ACN: 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Mr. Peter Marks Date of Last Notice: 3[rd] November 2010

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		12thDecember 2012
No. of securities held prior to change				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	43,111	-
		**Total **	43,111	-
Class		Unlisted Options
Number acquired				Options 1,000,000 - 1,000,000
			Shares	Options
		Direct	-	1,000,000
		Indirect	-	-
		Total	-	1,000,000

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		**Total **	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		As detailed in the Explanatory Memorandum which accompanied and formed part of the 2012 Notice of Annual General Meeting of the Company.
No. of securities held after change				Options 1,000,000 - 1,000,000
			Shares	Options
		Direct	-	1,000,000
		Indirect	43,111	-
		Total	43,111	1,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Issued in accordance with Resolution 5 as approved by shareholders at the Company’s Annual General Meeting held on 12thDecember 2012.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded No during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to N/A proceed during this period? If prior written clearance was provided on what date was this N/A provided?

==> picture [49 x 28] intentionally omitted <==

The CFO Solution

12 Dec 2012

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: Prana Biotechnology Limited (ASX:PBT) ACN: 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Mr. Brian Meltzer Date of Last Notice: 3[rd] November 2010

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		12thDecember 2012
No. of securities held prior to change				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	326,666	-
		**Total **	326,666	-
Class		Unlisted Options
Number acquired				Options 1,000,000 - 1,000,000
			Shares	Options
		Direct	-	1,000,000
		Indirect	-	-
		Total	-	1,000,000

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		**Total **	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		As detailed in the Explanatory Memorandum which accompanied and formed part of the 2012 Notice of Annual General Meeting of the Company.
No. of securities held after change				Options 1,000,000 - 1,000,000
			Shares	Options
		Direct	-	1,000,000
		Indirect	326,666	-
		Total	326,666	1,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Issued in accordance with Resolution 5 as approved by shareholders at the Company’s Annual General Meeting held on 12thDecember 2012.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded No during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to N/A proceed during this period? If prior written clearance was provided on what date was this N/A provided?

The CFO Solution

12 Dec 2012

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: Prana Biotechnology Limited (ASX:PBT) ACN: 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Mr. Lawrence Gozlan Date of Last Notice: 9[th] August 2011

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		12thDecember 2012
No. of securities held prior to change				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		**Total **	-	-
Class		Unlisted Options
Number acquired				Options 1,000,000 - 1,000,000
			Shares	Options
		Direct	-	1,000,000
		Indirect	-	-
		Total	-	1,000,000

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		**Total **	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		As detailed in the Explanatory Memorandum which accompanied and formed part of the 2012 Notice of Annual General Meeting of the Company.
No. of securities held after change				Options 1,000,000 - 1,000,000
			Shares	Options
		Direct	-	1,000,000
		Indirect	-	-
		Total	-	1,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Issued in accordance with Resolution 5 as approved by shareholders at the Company’s Annual General Meeting held on 12thDecember 2012.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded No during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to N/A proceed during this period? If prior written clearance was provided on what date was this N/A provided?

==> picture [49 x 28] intentionally omitted <==

The CFO Solution

12 Dec 2012

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002